• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

H.C. Wainwright 28th Annual Global Investment Conference

by admin | Sep 3, 2026 | Investor Presentations

ESMO IO: Refining Standard of Care in Advanced Melanoma

by chantal | Dec 12, 2025 | Investor Presentations

CEO Phil L’Huillier gives Report on Melanoma trial success to Proactive

by chantal | Dec 12, 2025 | Investor Presentations

Presentation of Year End Results: 11 September 2025

by chantal | Sep 12, 2025 | Investor Presentations

Scancell CEO on 2025 Milestones and Road ahead

by chantal | Sep 12, 2025 | Investor Presentations

« Older Entries

Recent Posts

  • Form F-4 (October 2026)
  • Preliminary Results for the year ended 30 April 2026
  • Atlantic crossing transforms outlook
  • Notice of General Meeting October 2026
  • Form of Proxy

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy